Investigation of The Effect of Adjuvant Endocrine Treatment on Depression, Sleep Quality and Sexual Function in Hormone Receptor-Positive Early-Stage Breast Cancer

INTRODUCTION: Questioning and recognizing depression, sleep and sexual dysfunctions in breast cancer patients improves the patients' quality of life. We aimed to evaluate the effects of adjuvant endocrine treatment and other variables on depression, sleep quality and sexual dysfunction in patients with early-stage breast cancer.
METHODS: Our study was performed with the participation of 105 patients who were diagnosed with hormone receptor positive, early stage (stage I-III) breast cancer and at least 3 months followed by the medical oncology outpatient clinic. Sociodemographic form, Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI) and Female Sexual Function Index (FSFI) were used as data collection tools.
RESULTS: According to the results obtained in our study, 55.8% patients had depression, 60.6% patients had poor sleep quality, 77.1% had poor sexual function. A tendency to sexual dysfunction was observed in patients with PR positivity and it was found to be statistically significant (P=0.005). There was a strong (p<0.001) correlation between the PSQI and BDI values of the patients. There was no significant relationship between different endocrine therapy agents (tamoxifen/anastrozole/letrozole) in patients with depression, sleep and sexual dysfunction (p> 0.05).
DISCUSSION AND CONCLUSION: In our study, we found a tendency to depression, sleep disturbance, and sexual dysfunction in most patients. It was revealed that some sociodemographic features, adjuvant treatment and hormone receptor status may affect sexual functionality. Therefore, these symptoms should be questioned in patients followed up with a diagnosis of breast cancer.

Hormon Reseptör Pozitif Erken Evre Meme Kanserinde Adjuvan Hormonal Tedavinin Depresyon, Uyku Kalitesi ve Cinsel Fonksiyon Üzerine Etkinliðinin Araþtýrýlmasý

GÝRÝÞ ve AMAÇ: Meme kanseri hastalarýnda depresyon, uyku ve cinsel iþlev bozukluklarýný sorgulamak ve tanýmak hastalarýn yaþam kalitesini iyileþtirmektedir. Erken evre meme kanserli hastalarda adjuvan endokrin tedavisi ve diðer deðiþkenlerin depresyon, uyku kalitesi ve cinsel iþlev bozukluðu üzerine etkilerini deðerlendirmeyi amaçladýk.
YÖNTEM ve GEREÇLER: Çalýþmamýz, hormon reseptörü pozitif, erken evre (evre I-III) meme kanseri tanýsý almýþ ve medikal onkoloji polikliniðinde en az 3 ay takip edilen 105 hastanýn katýlýmýyla gerçekleþtirildi. Veri toplama aracý olarak sosyodemografik form, Beck Depresyon Envanteri (BDI), Pittsburgh Uyku Kalitesi Ýndeksi (PSQI) ve Kadýn Cinsel Ýþlev Ýndeksi (FSFI) kullanýldý.
BULGULAR: Çalýþmamýzda elde ettiðimiz sonuçlara göre hastalarýn %55.8'inde depresyon, %60,6'sýnda kötü uyku kalitesi, %77.1'inde cinsel iþlev bozukluðu saptandý. PR pozitif olan hastalarda cinsel iþlev bozukluðuna eðilim gözlendi ve istatistiksel olarak anlamlý bulundu (P=0,005). Hastalarýn PUKÝ ve BDI deðerleri arasýnda güçlü (p<0,001) bir korelasyon vardý. Depresyon, uyku ve cinsel iþlev bozukluðu olan hastalarda farklý endokrin tedavi ajanlarý (tamoksifen/anastrozol/letrozol) arasýnda ise anlamlý bir iliþki yoktu (p> 0.05).
TARTIÞMA ve SONUÇ: Çalýþmamýzda çoðu hastada depresyon, uyku bozukluðu ve cinsel iþlev bozukluðuna eðilim saptadýk. Bazý sosyodemografik özelliklerin, adjuvan tedavi ve hormon reseptör durumunun cinsel iþlevselliði etkileyebileceði ortaya çýktý. Bu nedenle meme kanseri tanýsý ile takip edilen hastalarda bu belirtilerin sorgulanmasý ve deðerlendirilmesi önemlidir.